Literature DB >> 19203995

Epidermal growth factor-activated aryl hydrocarbon receptor nuclear translocator/HIF-1{beta} signal pathway up-regulates cyclooxygenase-2 gene expression associated with squamous cell carcinoma.

Kwang-Yu Chang1, Meng-Ru Shen, Mei-Yi Lee, Wen-Lin Wang, Wu-Chou Su, Wen-Chang Chang, Ben-Kuen Chen.   

Abstract

Hypoxia-inducible factor (HIF) accumulates when tumors grow under hypoxic conditions. The genesis of tumors, however, usually involves normoxic conditions. In this study, we were interested in examining the potential role of aryl hydrocarbon receptor nuclear translocator (ARNT)/HIF-1beta in tumor growth under normoxic conditions, specifically when cells are treated with epidermal growth factor (EGF), which is known to affect the gene expression of tumor growth-related protein COX-2 (cyclooxygenase-2). The results showed that EGF receptor inhibitor, AG1478, abolished EGF-induced nuclear accumulation of ARNT as well as the expression of COX-2. ARNT small interfering RNA inhibited the promoter activity, mRNA level, and protein expression of COX-2 in cells treated with EGF. In contrast, CoCl(2)-induced HIF-1alpha exhibited no effect on COX-2 expression. EGF also stimulated the formation of the ARNT.c-Jun complex as well as the complex binding to the COX-2 promoter. ARNT small interfering RNAs blocked EGF-activated cell migration. Moreover, COX-2 and ARNT were cohorts present distinctively in clinical specimens of human cervical squamous cell carcinoma and were almost nondetectable in adjacent normal or noncancerous cervical tissues. Our results revealed that ARNT plays an important role in EGF-regulated COX-2 gene expression and may thus be related to either a cause or a consequence of tumorigenesis in cervical cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19203995      PMCID: PMC2665114          DOI: 10.1074/jbc.M806210200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  49 in total

1.  Thioredoxin-1 modulates transcription of cyclooxygenase-2 via hypoxia-inducible factor-1alpha in non-small cell lung cancer.

Authors:  Ildiko Csiki; Kiyoshi Yanagisawa; Nobuhiro Haruki; Sorena Nadaf; Jason D Morrow; David H Johnson; David P Carbone
Journal:  Cancer Res       Date:  2006-01-01       Impact factor: 12.701

2.  Requirement of aryl hydrocarbon receptor overexpression for CYP1B1 up-regulation and cell growth in human lung adenocarcinomas.

Authors:  Jinghua Tsai Chang; Han Chang; Po-Hung Chen; Shong-Ling Lin; Pinpin Lin
Journal:  Clin Cancer Res       Date:  2007-01-01       Impact factor: 12.531

3.  Sp1 increases expression of cyclooxygenase-2 in hypoxic vascular endothelium. Implications for the mechanisms of aortic aneurysm and heart failure.

Authors:  Q Xu; Y S Ji; J F Schmedtje
Journal:  J Biol Chem       Date:  2000-08-11       Impact factor: 5.157

4.  Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.

Authors:  H Zhong; K Chiles; D Feldser; E Laughner; C Hanrahan; M M Georgescu; J W Simons; G L Semenza
Journal:  Cancer Res       Date:  2000-03-15       Impact factor: 12.701

5.  Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC).

Authors:  Shirish M Gadgeel; John C Ruckdeschel; Elisabeth I Heath; Lance K Heilbrun; Raghu Venkatramanamoorthy; Antoinette Wozniak
Journal:  J Thorac Oncol       Date:  2007-04       Impact factor: 15.609

6.  A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.

Authors:  Karen L Reckamp; Kostyantyn Krysan; Jason D Morrow; Ginger L Milne; Robert A Newman; Christopher Tucker; Robert M Elashoff; Steven M Dubinett; Robert A Figlin
Journal:  Clin Cancer Res       Date:  2006-06-01       Impact factor: 12.531

7.  The aryl hydrocarbon receptor repressor is a putative tumor suppressor gene in multiple human cancers.

Authors:  Enrique Zudaire; Natalia Cuesta; Vundavalli Murty; Karen Woodson; Lisa Adams; Nieves Gonzalez; Alfredo Martínez; Gopeshwar Narayan; Ilan Kirsch; Wilbur Franklin; Fred Hirsch; Michael Birrer; Frank Cuttitta
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

8.  Cyclooxygenase-2-derived prostaglandin E2 stimulates Id-1 transcription.

Authors:  Kotha Subbaramaiah; Robert Benezra; Clifford Hudis; Andrew J Dannenberg
Journal:  J Biol Chem       Date:  2008-10-08       Impact factor: 5.157

9.  EGFR activation results in enhanced cyclooxygenase-2 expression through p38 mitogen-activated protein kinase-dependent activation of the Sp1/Sp3 transcription factors in human gliomas.

Authors:  Kaiming Xu; Hui-Kuo G Shu
Journal:  Cancer Res       Date:  2007-07-01       Impact factor: 12.701

10.  Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group.

Authors:  Anuj Agarwala; William Fisher; Daniel Bruetman; John McClean; David Taber; Michael Titzer; Beth Juliar; Menggang Yu; Tim Breen; Lawrence H Einhorn; Nasser Hanna
Journal:  J Thorac Oncol       Date:  2008-04       Impact factor: 15.609

View more
  13 in total

1.  Involvement of aryl hydrocarbon receptor nuclear translocator in EGF-induced c-Jun/Sp1-mediated gene expression.

Authors:  Wan-Chen Huang; Shu-Ting Chen; Wei-Chiao Chang; Kwang-Yu Chang; Wen-Chang Chang; Ben-Kuen Chen
Journal:  Cell Mol Life Sci       Date:  2010-05-28       Impact factor: 9.261

Review 2.  Pathophysiological mechanisms of death resistance in colorectal carcinoma.

Authors:  Ching-Ying Huang; Linda Chia-Hui Yu
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

3.  PTX3 gene activation in EGF-induced head and neck cancer cell metastasis.

Authors:  Wei-Chiao Chang; Shuo-Lun Wu; Wan-Chen Huang; Jinn-Yuan Hsu; Shih-Hung Chan; Ju-Ming Wang; Jhih-Peng Tsai; Ben-Kuen Chen
Journal:  Oncotarget       Date:  2015-04-10

4.  Down-regulation of ARNT promotes cancer metastasis by activating the fibronectin/integrin β1/FAK axis.

Authors:  Chi-Ruei Huang; Chung-Ta Lee; Kwang-Yu Chang; Wen-Chang Chang; Yao-Wen Liu; Jenq-Chang Lee; Ben-Kuen Chen
Journal:  Oncotarget       Date:  2015-05-10

5.  An increase in reactive oxygen species by deregulation of ARNT enhances chemotherapeutic drug-induced cancer cell death.

Authors:  Jiunn-Min Shieh; Chih-Jie Shen; Wei-Chiao Chang; Hung-Chi Cheng; Ya-Yi Chan; Wan-Chen Huang; Wen-Chang Chang; Ben-Kuen Chen
Journal:  PLoS One       Date:  2014-06-12       Impact factor: 3.240

6.  Epidermal growth factor-induced cyclooxygenase-2 enhances head and neck squamous cell carcinoma metastasis through fibronectin up-regulation.

Authors:  Jinn-Yuan Hsu; Kwang-Yu Chang; Shang-Hung Chen; Chung-Ta Lee; Sheng-Tsung Chang; Hung-Chi Cheng; Wen-Chang Chang; Ben-Kuen Chen
Journal:  Oncotarget       Date:  2015-01-30

7.  Identification of ARNT-regulated BIRC3 as the target factor in cadmium renal toxicity.

Authors:  Jin-Yong Lee; Maki Tokumoto; Gi-Wook Hwang; Moo-Yeol Lee; Masahiko Satoh
Journal:  Sci Rep       Date:  2017-12-11       Impact factor: 4.379

8.  Oleate-induced PTX3 promotes head and neck squamous cell carcinoma metastasis through the up-regulation of vimentin.

Authors:  Shih-Hung Chan; Jhih-Peng Tsai; Chih-Jie Shen; Yu-Han Liao; Ben-Kuen Chen
Journal:  Oncotarget       Date:  2017-06-20

9.  Epidermal growth factor protects squamous cell carcinoma against cisplatin-induced cytotoxicity through increased interleukin-1β expression.

Authors:  Shian-Chin Ko; Chi-Ruei Huang; Jiunn-Min Shieh; Jhen-Hong Yang; Wen-Chang Chang; Ben-Kuen Chen
Journal:  PLoS One       Date:  2013-02-01       Impact factor: 3.240

10.  The novel Aryl hydrocarbon receptor inhibitor biseugenol inhibits gastric tumor growth and peritoneal dissemination.

Authors:  De-Wei Lai; Shing-Hwa Liu; Anna Isabella Karlsson; Wen-Jane Lee; Keh-Bin Wang; Yi-Ching Chen; Chin-Chang Shen; Sheng-Mao Wu; Chia-Yu Liu; Hsing-Ru Tien; Yen-Chun Peng; Yee-Jee Jan; Te-Hsin Chao; Keng-Hsin Lan; Jack L Arbiser; Meei-Ling Sheu
Journal:  Oncotarget       Date:  2014-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.